<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04762966</url>
  </required_header>
  <id_info>
    <org_study_id>2021PI020</org_study_id>
    <nct_id>NCT04762966</nct_id>
  </id_info>
  <brief_title>Study of Metformin Overdose</brief_title>
  <acronym>METINFO</acronym>
  <official_title>Study of Metformin Overdose in Adult Patients Treated at the University Hospital of Nancy: Single-center Descriptive Retrospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the METINFO study is an observational single-center retrospective and&#xD;
      descriptive study. The main objective is to estimate the real mortality rate associated to a&#xD;
      Metformin overdose. Second objectives are to estimate the real hospitalization rate related&#xD;
      to metformin overdose and to identify the risk factors of a metformin overdose and especially&#xD;
      the potential correlation between metformin blood concentration and overdose severity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of Mortality Rate</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimation of Hospitalization Rate</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of Risk Factors</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Metformin Associated Lactic Acidosis</condition>
  <arm_group>
    <arm_group_label>Therapeutic</arm_group_label>
    <description>Patients with metformin blood concentration in the therapeutic ranges.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supratherapeutic</arm_group_label>
    <description>Patients with metformin blood concentration above the therapeutic ranges.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Level of Metformin blood concentration</description>
    <arm_group_label>Supratherapeutic</arm_group_label>
    <arm_group_label>Therapeutic</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients benifiting of a metformin blood concentration determination in the period&#xD;
        ranging from the 1st of July 2019 and the 1st of July 2021 and hospitalized in the&#xD;
        university hospital of Nancy.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients benifiting of a metformin blood concentration determination in the&#xD;
             period ranging from the 1st of July 2019 and the 1st of July 2021.&#xD;
&#xD;
        Exclusion Criteria: None.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of Nancy</name>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien SCALA-BERTOLA, Dr</last_name>
      <phone>0383656138</phone>
      <email>j.scala-bertola@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Goonoo MS, Morris R, Raithatha A, Creagh F. Metformin-associated lactic acidosis: reinforcing learning points. BMJ Case Rep. 2020 Sep 2;13(9). pii: e235608. doi: 10.1136/bcr-2020-235608.</citation>
    <PMID>32878828</PMID>
  </reference>
  <reference>
    <citation>Walz L, Jönsson AK, Ahlner J, Östgren CJ, Druid H. Metformin - Postmortem fatal and non-fatal reference concentrations in femoral blood and risk factors associated with fatal intoxications. Forensic Sci Int. 2019 Oct;303:109935. doi: 10.1016/j.forsciint.2019.109935. Epub 2019 Aug 28.</citation>
    <PMID>31491622</PMID>
  </reference>
  <reference>
    <citation>Taub ES, Hoffman RS, Manini AF. Incidence and risk factors for hyperlactatemia in ED patients with acute metformin overdose. Am J Emerg Med. 2019 Dec;37(12):2205-2208. doi: 10.1016/j.ajem.2019.03.033. Epub 2019 Mar 23.</citation>
    <PMID>30967322</PMID>
  </reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 17, 2021</study_first_submitted>
  <study_first_submitted_qc>February 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2021</study_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>SCALA-BERTOLA Julien</investigator_full_name>
    <investigator_title>Dr Julien SCALA-BERTOLA</investigator_title>
  </responsible_party>
  <keyword>Metformin</keyword>
  <keyword>Lactic Acidosis</keyword>
  <keyword>Causality assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acidosis</mesh_term>
    <mesh_term>Acidosis, Lactic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

